标题
The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 9, Pages 3313
出版商
MDPI AG
发表日期
2020-05-08
DOI
10.3390/ijms21093313
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress
- (2020) Roberto Ronca et al. CANCER RESEARCH
- Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors
- (2020) Boichuk Sergei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
- (2019) Milena Urbini et al. GENES CHROMOSOMES & CANCER
- SO-003Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results
- (2019) I Matos et al. ANNALS OF ONCOLOGY
- FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
- (2019) Aroosha Raja et al. Cells
- Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression
- (2019) Sara Matarazzo et al. Cancers
- Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
- (2019) William A. Flavahan et al. NATURE
- Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
- (2019) John Nemunaitis et al. Future Oncology
- Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors
- (2018) Sergei Boichuk et al. ANTI-CANCER DRUGS
- A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
- (2018) Ciara M. Kelly et al. INVESTIGATIONAL NEW DRUGS
- FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p
- (2018) Jinglin Zhang et al. ONCOGENE
- Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
- (2018) Yemarshet K. Gebreyohannes et al. CLINICAL CANCER RESEARCH
- Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
- (2018) Sergei Boichuk et al. MOLECULES
- The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
- (2017) Margherita Nannini et al. Journal of Translational Medicine
- Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
- (2017) Maria A. Pantaleo et al. MOLECULAR CANCER RESEARCH
- A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
- (2017) Sergei Boichuk et al. MOLECULES
- Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
- (2016) E. Ben-Ami et al. ANNALS OF ONCOLOGY
- Targeting the fibroblast growth factor receptor family in cancer
- (2016) Niamh Hallinan et al. CANCER TREATMENT REVIEWS
- Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome
- (2016) Daniela Gasparotto et al. CLINICAL CANCER RESEARCH
- RNA sequencing validation of the Complexity INdex in SARComas prognostic signature
- (2016) Tom Lesluyes et al. EUROPEAN JOURNAL OF CANCER
- Genetic insights into the mechanisms of Fgf signaling
- (2016) J. Richard Brewer et al. GENES & DEVELOPMENT
- Transcriptome sequencing identifiesETV6-NTRK3as a gene fusion involved in GIST
- (2016) Monica Brenca et al. JOURNAL OF PATHOLOGY
- FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors
- (2016) Eileen Shi et al. Journal of Translational Medicine
- Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Dysregulated FGF signalling in neoplastic disorders
- (2016) Yasmine Tanner et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors
- (2016) Sosipatros A. Boikos et al. JAMA Oncology
- Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case
- (2015) Martin G. Belinsky et al. BMC CANCER
- FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors
- (2015) F. Li et al. Cancer Discovery
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
- (2014) A. Adenis et al. ANNALS OF ONCOLOGY
- Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
- (2014) Margherita Nannini et al. BMC CANCER
- Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance
- (2014) N. Javidi-Sharifi et al. CANCER RESEARCH
- Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
- (2014) A. P. Garner et al. CLINICAL CANCER RESEARCH
- Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations
- (2014) Maria A. Pantaleo et al. GENETICS IN MEDICINE
- Quadruplewild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
- (2014) Maria A. Pantaleo et al. Cancer Medicine
- A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib
- (2013) K. N. Ganjoo et al. ANNALS OF ONCOLOGY
- Endocrine Fibroblast Growth Factor FGF19 Promotes Prostate Cancer Progression
- (2013) S. Feng et al. CANCER RESEARCH
- Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST
- (2013) Maria A Pantaleo et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor
- (2013) J. Keith Killian et al. Cancer Discovery
- Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA
- (2013) Carol Beadling et al. Cancer Medicine
- Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
- (2012) M. J. Potthoff et al. GENES & DEVELOPMENT
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition
- (2012) Juliya Kalinina et al. STRUCTURE
- Succinate Dehydrogenase-Deficient GISTs
- (2011) Markku Miettinen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)
- (2011) Marc Daniels et al. CANCER LETTERS
- Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours
- (2011) Maria A Pantaleo et al. HISTOPATHOLOGY
- Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
- (2011) N. Itoh et al. JOURNAL OF BIOCHEMISTRY
- Biology of FGFRL1, the fifth fibroblast growth factor receptor
- (2010) Beat Trueb CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)
- (2010) Axel Le Cesne et al. EUROPEAN JOURNAL OF CANCER
- Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
- (2009) J.C. Soria et al. EUROPEAN JOURNAL OF CANCER
- Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target
- (2009) Maria A. Pantaleo et al. INTERNATIONAL JOURNAL OF CANCER
- The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
- (2009) E. D. Lew et al. Science Signaling
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search